MARLBOROUGH, Mass.--(BUSINESS WIRE)--Hologic, Inc. (Nasdaq: HOLX), a global leader in women's health, will launch the NovaSure® V5 global endometrial ablation (GEA) device at the American Association ...

“Since its launch over 20 years ago, we have constantly listened to our customers’ feedback, which has driven continuous design improvements for NovaSure,” said Jan Verstreken, Group President, ...

Please provide your email address to receive an email when new articles are posted on . Reintervention rates were higher for hysteroscopic myomectomy, uterine artery embolization and endometrial ...

Please provide your email address to receive an email when new articles are posted on . Live birth rates were similar for women with uterine fibroids who underwent radiofrequency ablation or ...

BERKELEY, Calif.--(BUSINESS WIRE)--Channel Medsystems, Inc., a medical device company whose mission is to empower every woman to take control of her health journey, today announced that the first ...

Surgical treatment options currently include hysteroscopic myomectomy, abdominal myomectomy, laparoscopic myomectomy, and endometrial ablation. Many women with fibroids can be treated with these ...

On March 20, Dr. Mitch Dizon, a subspecialist in Minimally Invasive Gynecologic Surgery at Erlanger Women’s Health, performed the region’s first laparoscopic radiofrequency ablation surgery for ...

CMS has approved ASCs as a site of service for transcervical uterine fibroid ablation — a minimally invasive procedure for symptomatic uterine fibroids that can be performed with the Sonata System ...

In the U.S., 26 million women aged 15 to 50 have uterine fibroids, or benign growths of the uterus, and more than half of those women will experience associated symptoms and health risks. Sign up for ...

Over the last 20 years, the NovaSure system has built a trusted legacy in GEA. The NovaSure device first received FDA approval in 2001, and by 2018 the NovaSure procedure had been used to treat over 3 ...